Show simple item record

dc.contributor.authorQutachi, Omaren
dc.contributor.authorWright, E. J.en
dc.contributor.authorBray, G.en
dc.contributor.authorHamid, O. A.en
dc.contributor.authorRose, F. R. A. J.en
dc.contributor.authorShakesheff, K. M.en
dc.contributor.authorDelcassian, D.en
dc.date.accessioned2018-09-05T09:47:24Z
dc.date.available2018-09-05T09:47:24Z
dc.date.issued2018-05-10
dc.identifier.citationQutachi, O., Wright, E.J., Bray, G. Hamid, O.A., Rose, F.R.A.J., Shakesheff, K.M., Delcassian, D. (2018) Improved delivery of PLGA microparticles and microparticle-cell scaffolds in clinical needle gauges using modified viscosity formulations. International Journal of Pharmaceutics, 546(1-2), pp. 272-278.en
dc.identifier.urihttp://eprints.nottingham.ac.uk/51868/
dc.identifier.urihttp://hdl.handle.net/2086/16537
dc.descriptionThe author's final peer reviewed version can be found by following the URI link. The Publisher's final version can be found by following the DOI link.en
dc.description.abstractPolymer microparticles are widely used as acellular drug delivery platforms in regenerative medicine, and have emerging potential as cellular scaffolds for therapeutic cell delivery. In the clinic, PLGA microparticles are typically administered intramuscularly or subcutaneously, with the clinician and clinical application site determining the precise needle gauge used for delivery. Here, we explored the role of needle diameter in microparticle delivery yield, and develop a modified viscosity formulation to improve microparticle delivery across a range of clinically relevant needle diameters. We have identified an optimal biocompatible formulation containing 0.25% pluronic F127 and 0.25% carboxymethyl cellulose, which can increase delivery payload to 520% across needle gauges 21–30G, and note that needle diameter impacts delivery efficacy. We use this formulation to increase the delivery yield of PLGA microparticles, and separately, PLGA-cell scaffolds supporting viable mesenchymal stem cells (MSCs), demonstrating the first in vitro delivery of this cell scaffold system. Together, these results highlight an optimal formulation for the delivery of microparticle and microparticle-cell scaffolds, and illustrate how careful choice of delivery formulation and needle size can dramatically impact delivery payload.en
dc.language.isoenen
dc.publisherElsevieren
dc.subjectHigh viscosity formulationen
dc.subjectMicroparticle deliveryen
dc.subjectCell particle scaffoldsen
dc.subjectNeedle gaugeen
dc.titleImproved delivery of PLGA microparticles and microparticle-cell scaffolds in clinical needle gauges using modified viscosity formulationsen
dc.typeArticleen
dc.identifier.doihttps://doi.org/10.1016/j.ijpharm.2018.05.025
dc.peerreviewedYesen
dc.funderUKRMP Acellular Hub and the EPSRC E-TERM programen
dc.projectidN/Aen
dc.cclicenceN/Aen
dc.date.acceptance2018-05-09en
dc.researchinstituteLeicester Institute for Pharmaceutical Innovation - From Molecules to Practice (LIPI)en
dc.exception.ref2021codes254aen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record